BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403. [PMID: 15197201 DOI: 10.1200/JCO.2004.08.154] [Cited by in Crossref: 322] [Cited by in F6Publishing: 340] [Article Influence: 17.9] [Reference Citation Analysis]
Number Citing Articles
1 Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 2022. [PMID: 36071285 DOI: 10.1038/s41571-022-00675-5] [Reference Citation Analysis]
2 Feng Y, Zhang C, Wu Z, Xu H, Zhang X, Feng C, Shao J, Xie M, Yang Y, Zhang Y, Ma T. Incorporation of liver chemistry score in predicting survival of liver-involved advanced gastric cancer patients who received palliative chemotherapy. Cancer Med 2022. [PMID: 36057969 DOI: 10.1002/cam4.5179] [Reference Citation Analysis]
3 Arigami T, Matsushita D, Okubo K, Shimonosono M, Sasaki K, Tsuruda Y, Kita Y, Tanabe K, Mori S, Yanagita S, Uenosono Y, Nakajo A, Kurahara H, Ohtsuka T. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer. Surg Today 2022. [PMID: 35543754 DOI: 10.1007/s00595-022-02515-6] [Reference Citation Analysis]
4 Sugiyama I, Ando K, Sadzuka Y. The Basic Study of Liposome in Temperature-Sensitive Gel at Body Temperature for Treatment of Peritoneal Dissemination. Gels 2022;8:252. [PMID: 35621550 DOI: 10.3390/gels8050252] [Reference Citation Analysis]
5 Shimozaki K, Shinozaki E, Yamamoto N, Imamura Y, Osumi H, Nakayama I, Wakatsuki T, Ooki A, Takahari D, Ogura M, Chin K, Watanabe M, Yamaguchi K. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol 2022. [PMID: 35438321 DOI: 10.1007/s00432-022-03966-7] [Reference Citation Analysis]
6 Marshall S, Wakatsuki T, Takahari D, Matsushima T, Ishizuka N, Nakayama I, Osumi H, Ogura M, Ichimura T, Shinozaki E, Chin K, Yamaguchi K. Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00815-1] [Reference Citation Analysis]
7 Naghashi S, Somi MH, Nikniaz Z. Pretreatment nutritional status is associated with quality of life in patients with gastric cancer: a cross-sectional study from Iran. Support Care Cancer 2022;30:3313-9. [PMID: 34985562 DOI: 10.1007/s00520-021-06792-8] [Reference Citation Analysis]
8 Nakasya A, Hagiwara Y, Ikoma T, Kurioka Y, Matsumoto T, Yamamoto Y, Tsuduki T, Kajiwara T, Moriwaki T, Nishina T, Yamashita N, Hyodo I. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study). Int J Clin Oncol 2022. [PMID: 35089459 DOI: 10.1007/s10147-022-02114-y] [Reference Citation Analysis]
9 Ma T, Wu Z, Zhang X, Xu H, Feng Y, Zhang C, Xie M, Yang Y, Zhang Y, Feng C, Sun G. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma. BMC Cancer 2021;21:1326. [PMID: 34895168 DOI: 10.1186/s12885-021-09079-7] [Reference Citation Analysis]
10 van Amelsfoort RM, van der Sluis K, Schats W, Jansen EPM, van Sandick JW, Verheij M, Walraven I. Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review. Cancers (Basel) 2021;13:5934. [PMID: 34885043 DOI: 10.3390/cancers13235934] [Reference Citation Analysis]
11 Xu H, Zhang X, Wu Z, Feng Y, Zhang C, Xie M, Yang Y, Zhang Y, Feng C, Ma T. Performances of Prognostic Models in Stratifying Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy: a Validation Study in a Chinese Cohort. J Gastric Cancer 2021;21:268-78. [PMID: 34691811 DOI: 10.5230/jgc.2021.21.e26] [Reference Citation Analysis]
12 Arai H, Inoue E, Yamaguchi K, Boku N, Hara H, Nishina T, Tsuda M, Shitara K, Shinozaki K, Nakamura S, Hyodo I, Muro K, Sasako M, Terashima M, Nakajima TE. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G. Cancer Med 2021;10:7673-82. [PMID: 34655175 DOI: 10.1002/cam4.4303] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 de la Fouchardiere C, Decoster L, Samalin E, Terret C, Kenis C, Droz JP, Coutzac C, Smyth E. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. Cancer Treat Rev 2021;100:102289. [PMID: 34583303 DOI: 10.1016/j.ctrv.2021.102289] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Chen GL, Huang Y, Zhang W, Pan X, Feng WJ, Zhao XY, Zhu XD, Li WH, Huang M, Chen ZY, Guo WJ. Three-Tier Prognostic Index in Young Adults With Advanced Gastric Cancer. Front Oncol 2021;11:667655. [PMID: 34568007 DOI: 10.3389/fonc.2021.667655] [Reference Citation Analysis]
15 Shimozaki K, Nakayama I, Takahari D, Kamiimabeppu D, Osumi H, Wakatsuki T, Ooki A, Ogura M, Shinozaki E, Chin K, Yamaguchi K. A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care. ESMO Open 2021;6:100234. [PMID: 34461485 DOI: 10.1016/j.esmoop.2021.100234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 van Kleef JJ, Dijksterhuis WPM, van den Boorn HG, Prins M, Verhoeven RHA, Gisbertz SS, Slingerland M, Mohammad NH, Creemers GJ, Neelis KJ, Heisterkamp J, Rosman C, Ruurda JP, Kouwenhoven EA, van de Poll-Franse LV, van Oijen MGH, Sprangers MAG, van Laarhoven HWM; Dutch Upper GI Cancer Group (DUCG). Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. Gastric Cancer 2021. [PMID: 34251543 DOI: 10.1007/s10120-021-01209-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Kim J, Hong JY, Kim ST, Park SH, Jekal SY, Choi JS, Chang DK, Kang WK, Seo SW, Lee J. Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. ESMO Open 2020;5:e000670. [PMID: 32188716 DOI: 10.1136/esmoopen-2020-000670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
18 Huang L, Jansen L, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Lagarde SM, Bastiaannet E, van de Velde CJH, Schrotz-King P, Brenner H. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. Ther Adv Med Oncol 2021;13:17588359211027837. [PMID: 34262618 DOI: 10.1177/17588359211027837] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Acikgoz Y, Aktürk Esen S, Ucar G, Dirikoc M, Ergun Y, Bal O, Uncu D. The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer. Cureus 2021;13:e14882. [PMID: 34104608 DOI: 10.7759/cureus.14882] [Reference Citation Analysis]
20 Petrillo A, Giunta EF, Pappalardo A, Bosso D, Attademo L, Cardalesi C, Diana A, Fabbrocini A, Fabozzi T, Giordano P, Ottaviano M, Rosanova M, Silvestri A, Federico P, Daniele B. Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. J Clin Med 2021;10:1777. [PMID: 33921760 DOI: 10.3390/jcm10081777] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yagi S, Yamada K, Terayama M, Wake H, Enomoto N, Nohara K, Takemura N, Kiyomatsu T, Kokudo N. Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer. Glob Health Med 2021;3:31-6. [PMID: 33688593 DOI: 10.35772/ghm.2020.01075] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Moss MCL, Aggarwal A, Qureshi A, Taylor B, Guerrero-Urbano T, Van Hemelrijck M. An assessment of the use of patient reported outcome measurements (PROMs) in cancers of the pelvic abdominal cavity: identifying oncologic benefit and an evidence-practice gap in routine clinical practice. Health Qual Life Outcomes 2021;19:20. [PMID: 33451330 DOI: 10.1186/s12955-020-01648-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Eum HH, Kwon M, Ryu D, Jo A, Chung W, Kim N, Hong Y, Son DS, Kim ST, Lee J, Lee HO, Park WY. Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. Exp Mol Med 2020;52:1976-88. [PMID: 33277616 DOI: 10.1038/s12276-020-00538-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
25 Toyota S, Orita H, Fukuyama Y, Motoyoshi S, Kawanami S, Maeda S, Kuramitsu E, Ichimanda M, Nagamatsu S, Nagata S, Kai S, Korenaga D, Mori M. Successful Conversion Surgery Following Chylous Ascites After Nivolumab for Advanced Gastric Cancer. In Vivo 2020;34:583-5. [PMID: 32111756 DOI: 10.21873/invivo.11810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Toyota S, Naito H, Motoyoshi S, Nakanishi R, Oki E, Orita H, Korenaga D. Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer. Surg Case Rep 2020;6:298. [PMID: 33237443 DOI: 10.1186/s40792-020-01040-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Akcay M, Etiz D, Celik O. Prediction of Survival and Recurrence Patterns by Machine Learning in Gastric Cancer Cases Undergoing Radiation Therapy and Chemotherapy. Adv Radiat Oncol 2020;5:1179-87. [PMID: 33305079 DOI: 10.1016/j.adro.2020.07.007] [Reference Citation Analysis]
28 Akcay M, Etiz D, Celik O. Prediction of Survival and Recurrence Patterns by Machine Learning in Gastric Cancer Cases Undergoing Radiation Therapy and Chemotherapy. Advances in Radiation Oncology 2020;5:1179-87. [DOI: 10.1016/j.adro.2020.07.007] [Reference Citation Analysis]
29 Zhou Q, Lan X, Li N, Yuan D, Zhang J. Analysis of Prognostic Factors and Design of Prognosis Model for Patients with Stage IV Gastric Cancer Following First-Line Palliative Chemotherapy. Cancer Manag Res 2020;12:10461-8. [PMID: 33122945 DOI: 10.2147/CMAR.S263320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Akcay M, Etiz D, Celik O. Prediction of Survival and Recurrence Patterns by Machine Learning in Gastric Cancer Cases Undergoing Radiation Therapy and Chemotherapy. Adv Radiat Oncol. 2020;5:1179-1187. [PMID: 33305079 DOI: 10.1016/j.adro.2020.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
31 Matsumoto T, Yamamoto Y, Kuriona Y, Okazaki U, Kimura S, Miura K, Tsuduki T, Watanabe T, Mastumoto Y, Takatani M. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses. BMC Cancer 2020;20:684. [PMID: 32698781 DOI: 10.1186/s12885-020-07176-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
32 Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. BMC Cancer 2020;20:548. [PMID: 32532230 DOI: 10.1186/s12885-020-07047-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jeong GS, Lee IS, Park YS, Kim BS, Yoo MW, Yook JH, Kim BS. Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers. J Gastric Cancer 2020;20:233-44. [PMID: 33024580 DOI: 10.5230/jgc.2020.20.e20] [Reference Citation Analysis]
34 Luo HS, Xu HY, Du ZS, Li XY, Wu SX, Huang HC, Lin LX. Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy. Front Oncol 2020;10:430. [PMID: 32351882 DOI: 10.3389/fonc.2020.00430] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Iwasa S, Kudo T, Takahari D, Hara H, Kato K, Satoh T. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol 2020;25:1223-32. [PMID: 32347434 DOI: 10.1007/s10147-020-01684-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
36 Liu CT, Hong CQ, Huang XC, Li EM, Xu YW, Peng YH. Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer. J Cancer 2020;11:4332-42. [PMID: 32489452 DOI: 10.7150/jca.44545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhou D, Wu Y, Zhu Y, Lin Z, Yu D, Zhang T. The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy. J Cancer 2020;11:4205-12. [PMID: 32368303 DOI: 10.7150/jca.39575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
38 Hamamoto Y, Piao Y, Makiyama A. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites. Gastric Cancer 2020;23:363-72. [PMID: 32236760 DOI: 10.1007/s10120-020-01067-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
39 Özçelik M, Ercelep Ö, Keser S, Özdemir Barışık N, Başar M, Odabaş H, Oyman A, Işık S, Özçelik S, Aliustaoğlu M. PTK-7 Expression in Gastric Cancer: A Prognostic Determinant. Balkan Med J 2020;37:91-7. [PMID: 31820857 DOI: 10.4274/balkanmedj.galenos.2019.2019.8.12] [Reference Citation Analysis]
40 Kinoshita H, Kamoda H, Ishii T, Hagiwara Y, Tsukanishi T, Amanuma Y, Nankinzan R, Orita S, Inage K, Hirosawa N, Ohtori S, Yonemoto T. Successful Neurological Recovery with Multimodality Therapy without Surgery for Spinal Metastases from Advanced Gastric Cancer. Case Rep Orthop 2020;2020:4753027. [PMID: 32089929 DOI: 10.1155/2020/4753027] [Reference Citation Analysis]
41 Mehta R, Kommalapati A, Kim RD. The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer. Cancer Manag Res 2020;12:51-7. [PMID: 32021422 DOI: 10.2147/CMAR.S199827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
42 Yonemura Y, Prabhu A, Sako S, Ishibashi H, Mizumoto A, Takao N, Ichinose M, Motoi S, Liu Y, Nishihara K, Brandl A, Fushida S. Long Term Survival after Cytoreductive Surgery Combined with Perioperative Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis. Cancers (Basel) 2020;12:E116. [PMID: 31906405 DOI: 10.3390/cancers12010116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
43 Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q, Liao Q, Yang X, Guan T, Liang H, Cui S, On Behalf Of The Chinese Peritoneal Oncology Study Group. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study. Chin J Cancer Res 2020;32:794-803. [PMID: 33447001 DOI: 10.21147/j.issn.1000-9604.2020.06.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
44 Seo S, Ryu MH, Ryoo BY, Park Y, Park YS, Na YS, Lee CW, Lee JK, Kang YK. Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy. Chin J Cancer Res 2019;31:620-31. [PMID: 31564805 DOI: 10.21147/j.issn.1000-9604.2019.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Smyth EC, Moehler M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol. 2019;11:1758835919867522. [PMID: 31489035 DOI: 10.1177/1758835919867522] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
46 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
47 Qiu H. Complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases: results of a propensity score matching analysis from France. Cancer Commun (Lond) 2019;39:45. [PMID: 31395093 DOI: 10.1186/s40880-019-0391-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 de Man FM, van Eerden RAG, Oomen-de Hoop E, Veraart JN, van Doorn N, van Doorn L, van der Gaast A, Mathijssen RHJ. Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. Cancers (Basel) 2019;11:E826. [PMID: 31200588 DOI: 10.3390/cancers11060826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Mitani S, Kadowaki S, Hasegawa H, Wakatsuki T, Hara H, Tajika M, Nishikawa K, Hirao M, Takahari D, Chin K, Muro K. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. Int J Clin Oncol 2019;24:1197-203. [PMID: 31152323 DOI: 10.1007/s10147-019-01477-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, Grootscholten C, Snaebjornsson P, Retel VP, van Tinteren H, Vanhoutvin S, van der Noort V, Houwink A, Hahn C, Huitema ADR, Lahaye M, Los M, van den Barselaar P, Imhof O, Aalbers A, van Dam GM, van Etten B, Wijnhoven BPL, Luyer MDP, Boerma D, van Sandick JW. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy vs palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19:420. [PMID: 31060544 DOI: 10.1186/s12885-019-5640-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
51 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
52 Takeuchi M, Kawakubo H, Mayanagi S, Suzuki Y, Okabayashi K, Yamashita T, Kamiya S, Irino T, Fukuda K, Nakamura R, Suda K, Wada N, Takeuchi H, Kitagawa Y. Perioperative risk calculator for distal gastrectomy predicts overall survival in patients with gastric cancer. Gastric Cancer 2019;22:624-31. [PMID: 30478691 DOI: 10.1007/s10120-018-0896-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, Suzuki T, Ota Y, Nakayama I, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther 2018;11:8301-7. [PMID: 30538499 DOI: 10.2147/OTT.S184665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
54 Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: A review. World J Gastrointest Oncol 2018; 10(11): 398-409 [PMID: 30487951 DOI: 10.4251/wjgo.v10.i11.398] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
55 Hesam S, Mahmoudi M, Rahimi Foroushani A, Yaseri M, Mansournia MA. A Spatial Survival Model in Presence of Competing Risks for Iranian Gastrointestinal Cancer Patients. Asian Pac J Cancer Prev 2018;19:2947-54. [PMID: 30362330 DOI: 10.22034/APJCP.2018.19.10.2947] [Reference Citation Analysis]
56 Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer 2019;22:577-86. [PMID: 30311042 DOI: 10.1007/s10120-018-0885-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
57 Sato S, Kunisaki C, Suematsu H, Tanaka Y, Miyamoto H, Kosaka T, Yukawa N, Tanaka K, Sato K, Akiyama H, Endo I. Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy. In Vivo 2018;32:603-10. [PMID: 29695567 DOI: 10.21873/invivo.11282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
58 Fornaro L, Vasile E, Falcone A. Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. J Clin Oncol 2016;34:3822-3. [PMID: 27528730 DOI: 10.1200/JCO.2016.68.6931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
59 Bruton Joe M, Truong PT. Abscopal Effect after Palliative Radiation Therapy for Metastatic Adenocarcinoma of the Esophagus. Cureus. 2018;10:e3089. [PMID: 30333943 DOI: 10.7759/cureus.3089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
60 Hesam S, Mahmoudi M, Foroushani AR, Yaseri M, Mansournia MA. A cause-specific hazard spatial frailty model for competing risks data. Spatial Statistics 2018;26:101-24. [DOI: 10.1016/j.spasta.2018.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, Rha SY, Park K. A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. AAPS J 2018;20:72. [PMID: 29845329 DOI: 10.1208/s12248-018-0223-8] [Reference Citation Analysis]
62 Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, Lefor AK, Sata N. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2:116-123. [PMID: 29863151 DOI: 10.1002/ags3.12060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
63 Paulson AS, Hess LM, Liepa AM, Cui ZL, Aguilar KM, Clark J, Schelman W. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer 2018;21:831-44. [PMID: 29397460 DOI: 10.1007/s10120-018-0796-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
64 Narita Y, Kadowaki S, Oze I, Kito Y, Kawakami T, Machida N, Taniguchi H, Ura T, Ando M, Ito S, Tajika M, Yatabe Y, Yasui H, Muro K. Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. J Gastrointest Oncol 2018;9:52-63. [PMID: 29564171 DOI: 10.21037/jgo.2017.11.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
65 Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer. 2018;18:120. [PMID: 29385993 DOI: 10.1186/s12885-018-4057-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
66 Romain B, Rohmer O, Schimchowitsch S, Hübner M, Delhorme JB, Brigand C, Rohr S, Guenot D. Influence of preoperative life satisfaction on recovery and outcomes after colorectal cancer surgery - a prospective pilot study. Health Qual Life Outcomes 2018;16:16. [PMID: 29343246 DOI: 10.1186/s12955-017-0824-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Li Q, Wen F, Zhou C, Qiu M, Liu J, Chen J, Yi C, Li Z, Luo D, Xu F, Cai X, Bi F; Western Cooperative Gastrointestinal Oncology Group of China. Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study. Oncotarget 2017;8:97890-9. [PMID: 29228659 DOI: 10.18632/oncotarget.18426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
68 Amdal CD, Jacobsen AB, Falk RS, Johnson E, Os SS, Warloe T, Bjordal K. Improved treatment decisions in patients with esophageal cancer. Acta Oncol 2017;56:1286-94. [PMID: 28686501 DOI: 10.1080/0284186X.2017.1346379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Wu F, Shi C, Wu R, Huang Z, Chen Q. Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases. Oncotarget 2017;8:78120-32. [PMID: 29100454 DOI: 10.18632/oncotarget.17696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Tian X, Zhu X, Yan T, Yu C, Shen C, Hu Y, Hong J, Chen H, Fang JY. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer. Mol Oncol 2017;11:1544-60. [PMID: 28796930 DOI: 10.1002/1878-0261.12117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
71 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 230] [Article Influence: 15.4] [Reference Citation Analysis]
72 Zhou X, Qiu GQ, Bao WA, Zhang DH. The prognostic role of nutrition risk score (NRS) in patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC). Oncotarget 2017;8:77465-73. [PMID: 29100401 DOI: 10.18632/oncotarget.20530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, Park SR. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric Cancer. 2018;21:453-463. [PMID: 28828688 DOI: 10.1007/s10120-017-0756-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
74 Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer 2018;21:473-80. [PMID: 28815316 DOI: 10.1007/s10120-017-0754-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
75 Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World J Gastrointest Oncol 2017; 9(8): 333-340 [PMID: 28868114 DOI: 10.4251/wjgo.v9.i8.333] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
76 Tian X, Zhu X, Yan T, Yu C, Shen C, Hong J, Chen H, Fang JY. Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis. J Cancer 2017;8:2575-86. [PMID: 28900495 DOI: 10.7150/jca.19980] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
77 Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open 2017;2:e000206. [PMID: 29209523 DOI: 10.1136/esmoopen-2017-000206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
78 Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer 2017;17:132-44. [PMID: 28680718 DOI: 10.5230/jgc.2017.17.e16] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
79 Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez ML, Viudez A, Hernández R, Cano JM, Echavarria I, Pericay C, Mangas M, Visa L, Buxo E, García T, Rodríguez Palomo A, Álvarez Manceñido F, Lacalle A, Macias I, Azkarate A, Ramchandani A, Fernández Montes A, López C, Longo F, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Hurtado A, Madero R, Gómez C, Gallego J. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. Br J Cancer 2017;116:1526-35. [PMID: 28463962 DOI: 10.1038/bjc.2017.122] [Cited by in Crossref: 24] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
80 Cho H, Ryu MH, Kim KP, Ryoo BY, Park SR, Kim BS, Lee IS, Kim HS, Yoo MW, Yook JH, Oh ST, Kim BS, Kang YK. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. Gastric Cancer 2017;20:970-7. [PMID: 28303362 DOI: 10.1007/s10120-017-0710-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
81 Takahari D, Mizusawa J, Koizumi W, Hyodo I, Boku N. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials. Gastric Cancer 2017;20:757-63. [PMID: 28205060 DOI: 10.1007/s10120-017-0702-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
82 Ochenduszko S, Puskulluoglu M, Konopka K, Fijorek K, Slowik AJ, Pędziwiatr M, Budzyński A. Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. Ther Adv Med Oncol 2017;9:223-33. [PMID: 28491144 DOI: 10.1177/1758834016689029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
83 Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2017;20:825-833. [PMID: 28028664 DOI: 10.1007/s10120-016-0681-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
84 Beeharry MK, Liu WT, Yao XX, Yan M, Zhu ZG. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol 2016;1:77. [PMID: 28138643 DOI: 10.21037/tgh.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
85 Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N. Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study. Biopsychosoc Med 2016;10:24. [PMID: 27478498 DOI: 10.1186/s13030-016-0075-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34:2736-2742. [PMID: 27382098 DOI: 10.1200/jco.2015.65.5092] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
87 Wang J, Qu J, Li Z, Che X, Zhang J, Liu J, Teng Y, Jin B, Zhao M, Liu Y, Qu X. A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy. Transl Oncol 2016;9:256-61. [PMID: 27267846 DOI: 10.1016/j.tranon.2016.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
88 Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20:254-262. [PMID: 27147244 DOI: 10.1007/s10120-016-0613-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
89 Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, Liepa AM. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes 2016;14:52. [PMID: 27016084 DOI: 10.1186/s12955-016-0449-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
90 Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol 2016; 22(11): 3069-3077 [PMID: 27003986 DOI: 10.3748/wjg.v22.i11.3069] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
91 Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D. Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Ther Adv Med Oncol 2016;8:104-12. [PMID: 26929786 DOI: 10.1177/1758834015621669] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
92 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
93 Seshadri RA, Glehen O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol 2016;7:198-207. [PMID: 27065710 DOI: 10.1007/s13193-016-0502-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
94 Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016; 22(3): 1114-1130 [PMID: 26811651 DOI: 10.3748/wjg.v22.i3.1114] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
95 Esfahani A, Makhdami N, Faramarzi E, Asghari Jafarabadi M, Ostadrahimi A, Ghayour Nahand M, Ghoreishi Z. Prealbumin/CRP Based Prognostic Score, a New Tool for Predicting Metastasis in Patients with Inoperable Gastric Cancer. Gastroenterol Res Pract 2016;2016:4686189. [PMID: 26904109 DOI: 10.1155/2016/4686189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
96 Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer 2016;7:88-94. [PMID: 26722364 DOI: 10.7150/jca.13248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
97 Jung JY, Ryu MH, Ryoo BY, Han B, Cho JW, Lim MS, Lim H, Kang HS, Kim MJ, Ha HI, Song H, Kim JH, Kim HS, Kang YK, Zang DY. Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. Gastroenterol Res Pract 2016;2016:6857625. [PMID: 26839542 DOI: 10.1155/2016/6857625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
98 Oholendt AL, Zadlo JL. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol 2015;6:71-5. [PMID: 26413377 DOI: 10.6004/jadpro.2015.6.1.8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
99 Ochenduszko S, Puskulluoglu M, Konopka K, Fijorek K, Urbanczyk K, Budzynski A, Matlok M, Lazar A, Sinczak-Kuta A, Pedziwiatr M, Krzemieniecki K. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Med Oncol 2015;32:242. [PMID: 26354521 DOI: 10.1007/s12032-015-0687-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
100 Wei XL, Zhang DS, He MM, Jin Y, Wang DS, Zhou YX, Bai L, Li ZZ, Luo HY, Wang FH, Xu RH. The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumour Biol 2016;37:1879-87. [PMID: 26323257 DOI: 10.1007/s13277-015-3851-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
101 Suk H, Kwon OK, Yu W. Preoperative Quality of Life in Patients with Gastric Cancer. J Gastric Cancer. 2015;15:121-126. [PMID: 26161285 DOI: 10.5230/jgc.2015.15.2.121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
102 Zhang W, Yu Y, Fang Y, Wang Y, Cui Y, Shen K, Liu T. Systemic chemotherapy as a main strategy for liver metastases from gastric cancer. Clin Transl Oncol. 2015;17:888-894. [PMID: 26108406 DOI: 10.1007/s12094-015-1321-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
103 Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2015;Epub ahead of print. [PMID: 25862567 DOI: 10.1007/s10120-015-0495-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
104 Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer 2015;15:128. [PMID: 25872762 DOI: 10.1186/s12885-015-1114-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
105 Groene O, Crosby T, Hardwick RH, Riley S, Greenaway K, Cromwell D. A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer. BMJ Open 2015;5:e006724. [PMID: 25740023 DOI: 10.1136/bmjopen-2014-006724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
106 Hamamoto Y. Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Mol Clin Oncol 2015;3:539-42. [PMID: 26137263 DOI: 10.3892/mco.2015.510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
107 Zhu L, Li Z, Wang Y, Zhang C, Liu Y, Qu X. Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3:699-705. [PMID: 26137290 DOI: 10.3892/mco.2015.506] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
108 Collins A, Hatzaras I, Schmidt C, Carruthers K, Melvin WS, Muscarella P, Ellison EC, Martin E, Bloomston M. Gastrectomy in advanced gastric cancer effectively palliates symptoms and may improve survival in select patients. J Gastrointest Surg 2014;18:491-6. [PMID: 24234246 DOI: 10.1007/s11605-013-2415-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
109 Schildberg CW, Weidinger T, Hohenberger W, Wein A, Langheinrich M, Neurath M, Boxberger F. Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg. 2014;38:419-425. [PMID: 24146196 DOI: 10.1007/s00268-013-2293-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
110 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
111 Steel JL, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, Tsung A. Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer 2014;120:3717-21. [PMID: 25104581 DOI: 10.1002/cncr.28902] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
112 Zhu X, Zhao X, Peng W, Sun S, Cao J, Ji D, Liu X, Wang C, Huang M, Yu H, Guo W, Li J, Yin J. Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors. J Cancer Res Clin Oncol 2015;141:109-18. [PMID: 25035248 DOI: 10.1007/s00432-014-1754-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
113 Adams HL, Jaunoo SS. Clinical significance of incidental findings on staging positron emission tomography for oesophagogastric malignancies. Ann R Coll Surg Engl 2014;96:207-10. [PMID: 24780785 DOI: 10.1308/003588414X13814021678871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
114 Suner A, Buyukhatipoglu H, Balakan O, Kalender ME, Ulas T, Sevinc A, Camci C. Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report. Case Rep Oncol Med 2014;2014:731581. [PMID: 24822142 DOI: 10.1155/2014/731581] [Reference Citation Analysis]
115 Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, Goto M, Nishina T, Tamura T, Tsuji A, Ohtsu A. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist 2014;19:358-66. [PMID: 24668328 DOI: 10.1634/theoncologist.2013-0306] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
116 Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7): 1635-1649 [PMID: 24587643 DOI: 10.3748/wjg.v20.i7.1635] [Cited by in CrossRef: 365] [Cited by in F6Publishing: 362] [Article Influence: 45.6] [Reference Citation Analysis]
117 Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014;464:367-78. [DOI: 10.1007/s00428-013-1533-y] [Cited by in Crossref: 95] [Cited by in F6Publishing: 106] [Article Influence: 11.9] [Reference Citation Analysis]
118 Khan K, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife LR, Banerji U, de Bono JS, Cunningham D, Kaye SB. Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer 2014;17:621-9. [PMID: 24445485 DOI: 10.1007/s10120-013-0328-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
119 Ahmed I, Debray TP, Moons KG, Riley RD. Developing and validating risk prediction models in an individual participant data meta-analysis. BMC Med Res Methodol 2014;14:3. [PMID: 24397587 DOI: 10.1186/1471-2288-14-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
120 Jung HA, Adenis A, Lee J, Park SH, Maeng CH, Park S, Ahn HK, Shim YM, Penel N, Im YH. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. Cancer Res Treat 2013;45:285-94. [PMID: 24454001 DOI: 10.4143/crt.2013.45.4.285] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
121 Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, Zhou B, Xu H. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:577. [PMID: 24304886 DOI: 10.1186/1471-2407-13-577] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 6.6] [Reference Citation Analysis]
122 Xu J, Evans TJ, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience 2013;7:351. [PMID: 24062809 DOI: 10.3332/ecancer.2013.351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
123 Zhu L, Luo W, Wei J, Zou C. High efficacy of combination chemotherapy with S-1 and low-dose docetaxel for the treatment of highly advanced gastric cancer with peritoneal dissemination: A case report. Oncol Lett 2013;5:1509-12. [PMID: 23761814 DOI: 10.3892/ol.2013.1237] [Reference Citation Analysis]
124 Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol 2013;139:1383-9. [PMID: 23708301 DOI: 10.1007/s00432-013-1452-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
125 Lv ZD, Wang HB, Dong Q, Kong B, Li JG, Yang ZC, Qu HL, Cao WH, Xu HM. Mesothelial cells differentiate into fibroblast-like cells under the scirrhous gastric cancer microenvironment and promote peritoneal carcinomatosis in vitro and in vivo. Mol Cell Biochem 2013;377:177-85. [PMID: 23392771 DOI: 10.1007/s11010-013-1583-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
126 Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M, Li X, Li S, Tang H. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology 2013;57:667-77. [PMID: 22996586 DOI: 10.1002/hep.26071] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 9.1] [Reference Citation Analysis]
127 Kanat O, O’Neil BH. Metastatic gastric cancer treatment: a little slow but worthy progress. Med Oncol. 2013;30:464. [PMID: 23335104 DOI: 10.1007/s12032-013-0464-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
128 Sekikawa A, Fukui H, Zhang X, Maruo T, Tsumura T, Okabe Y, Wakasa T, Osaki Y, Chiba T, Tomita T, Oshima T, Watari J, Miwa H. REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer. Br J Cancer 2013;108:395-401. [PMID: 23322208 DOI: 10.1038/bjc.2012.572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
129 Ito H, Inoue H, Odaka N, Satodate H, Suzuki M, Mukai S, Takehara Y, Kida H, Kudo SE. Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study. J Exp Clin Cancer Res 2013;32:2. [PMID: 23289488 DOI: 10.1186/1756-9966-32-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
130 Lordick F. To resect or not resect in metastatic gastric cancer: that is the question! Gastric Cancer 2012;15:229-31. [PMID: 22282136 DOI: 10.1007/s10120-011-0136-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
131 Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol 2013;139:595-603. [PMID: 23250506 DOI: 10.1007/s00432-012-1349-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Lu Z, Lu M, Zhang X, Li J, Zhou J, Gong J, Gao J, Li J, Zhang X, Li Y. Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments. Clin Transl Oncol. 2013;15:376-383. [PMID: 23054754 DOI: 10.1007/s00432-013-1537-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
133 Lu Z, Lu M, Zhang X, Li J, Zhou J, Gong J, Gao J, Li J, Zhang X, Li Y, Shen L. Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments. Clin Transl Oncol 2013;15:376-83. [PMID: 23054754 DOI: 10.1007/s12094-012-0938-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
134 Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012;12:438. [PMID: 23020584 DOI: 10.1186/1471-2407-12-438] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
135 Li TC, Li CI, Tseng CH, Lin KS, Yang SY, Chen CY, Hsia TC, Lee YD, Lin CC. Quality of life predicts survival in patients with non-small cell lung cancer. BMC Public Health 2012;12:790. [PMID: 22978682 DOI: 10.1186/1471-2458-12-790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
136 Schildberg CW, Croner R, Merkel S, Schellerer V, Müller V, Yedibela S, Hohenberger W, Peros G, Perrakis A. Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis. World J Surg 2012;36:872-8. [PMID: 22354489 DOI: 10.1007/s00268-012-1492-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
137 Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, Jeon HM, Hong YS. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16:290-300. [PMID: 22898806 DOI: 10.1007/s10120-012-0182-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
138 Hwang JE, Kim HN, Kim DE, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status. Exp Ther Med 2012;4:562-8. [PMID: 23170106 DOI: 10.3892/etm.2012.644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
139 Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39:9473-9484. [PMID: 22729879 DOI: 10.1007/s11033-012-1812-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
140 Syrios J, Sougioultzis S, Xynos ID, Kavantzas N, Kosmas C, Agrogiannis G, Griniatsos J, Karavokyros I, Pikoulis E, Patsouris ES, Tsavaris N. Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer 2012;12:264. [PMID: 22892134 DOI: 10.1186/1471-2407-12-264] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
141 Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol 2012;5:155-9. [PMID: 22741034 DOI: 10.1596/tlo.12151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
142 Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer. 2012;15:265-280. [PMID: 22576708 DOI: 10.1007/s10120-012-0151-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
143 Liu X, Cai H, Wang Y. Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol. 2012;10:68. [PMID: 22540862 DOI: 10.1186/1477-7819-10-68] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
144 Cheong JC, Choi WH, Kim DJ, Park JH, Cho SJ, Choi CS, Kim JS. Prognostic significance of computed tomography defined ascites in advanced gastric cancer. J Korean Surg Soc. 2012;82:219-226. [PMID: 22493762 DOI: 10.4174/jkss.2012.82.4.219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
145 Shitara K, Mizota A, Matsuo K, Sato Y, Kondo C, Takahari D, Ura T, Tajika M, Muro K. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16:48-55. [PMID: 22362376 DOI: 10.1007/s10120-012-0143-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
146 Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One. 2011;6:e29670. [PMID: 22216342 DOI: 10.1371/journal.pone.0029670] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
147 Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, Miyata Y, Takiuchi H, Yamaguchi K, Sasaki Y, Nishina T, Satoh A, Baba E, Tamura T, Abe T, Hatake K, Ohtsu A. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2012;15:313-22. [PMID: 22179434 DOI: 10.1007/s10120-011-0118-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
148 Dorcaratto D, Grande L, Ramón J, Pera M. Quality of Life of Patients With Cancer of the Oesophagus and Stomach. Cirugía Española (English Edition) 2011;89:635-44. [DOI: 10.1016/j.cireng.2011.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
149 Lee SR, Kim HO, Yoo CH. Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer. J Korean Surg Soc. 2011;81:163-168. [PMID: 22066117 DOI: 10.4174/jkss.2011.81.3.163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
150 Lei KF, Liu BY, Zhang XQ, Jin XL, Guo Y, Ye M, Zhu ZG. Development of a survival prediction model for gastric cancer using serine proteases and their inhibitors. Exp Ther Med 2012;3:109-16. [PMID: 22969854 DOI: 10.3892/etm.2011.353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
151 Shitara K, Ikeda J, Kondo C, Takahari D, Ura T, Muro K, Matsuo K. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer 2012;15:137-43. [PMID: 21842172 DOI: 10.1007/s10120-011-0083-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
152 Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011;3:257-66. [PMID: 21792334 DOI: 10.2147/CMR.S12713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
153 Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Indian J Surg Oncol. 2011;2:16-23. [PMID: 22696066 DOI: 10.1007/s13193-011-0074-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
154 Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 2011;14:249-56. [PMID: 21431297 DOI: 10.1007/s10120-011-0032-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
155 Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 2011;14:219-225. [PMID: 21409520 DOI: 10.1007/s10120-011-0031-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
156 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco.2009.26.6114] [Cited by in Crossref: 387] [Cited by in F6Publishing: 408] [Article Influence: 32.3] [Reference Citation Analysis]
157 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco2009.26.6114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Lv ZD, Na D, Liu FN, Du ZM, Sun Z, Li Z, Ma XY, Wang ZN, Xu HM. Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis. J Exp Clin Cancer Res. 2010;29:139. [PMID: 21034459 DOI: 10.1186/1756-9966-29-139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
159 Lim do H, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, Kwon JM, Lee SC, Lee HY, Kim HS. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2010;10:583. [PMID: 20977739 DOI: 10.1186/1471-2407-10-583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
160 Shitara K, Takahari D. A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy. Case Rep Oncol 2010;3:262-7. [PMID: 20740208 DOI: 10.1159/000319169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
161 Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol 2010; 2(7): 287-294 [PMID: 21160659 DOI: 10.4251/wjgo.v2.i7.287] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
162 Hashimoto K, Takashima A, Nagashima K, Okazaki SS, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 2010;136:1059-64. [PMID: 20037789 DOI: 10.1007/s00432-009-0752-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
163 Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci. 2011;56:131-138. [PMID: 20503071 DOI: 10.1007/s10620-010-1280-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
164 Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102:475-481. [PMID: 20068567 DOI: 10.1038/sj.bjc.6605522] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
165 Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102. [PMID: 20030832 DOI: 10.1186/1477-7525-7-102] [Cited by in Crossref: 309] [Cited by in F6Publishing: 321] [Article Influence: 23.8] [Reference Citation Analysis]
166 Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624-1632. [PMID: 19920223 DOI: 10.1093/jnci/djp386] [Cited by in Crossref: 351] [Cited by in F6Publishing: 370] [Article Influence: 27.0] [Reference Citation Analysis]
167 van Heijl M, Sprangers MA, de Boer AG, Lagarde SM, Reitsma HB, Busch OR, Tilanus HW, van Lanschot JJ, van Berge Henegouwen MI. Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol 2010;17:23-30. [PMID: 19830496 DOI: 10.1245/s10434-009-0731-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
168 Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Bugat R. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res 2009;18:853-61. [PMID: 19568958 DOI: 10.1007/s11136-009-9493-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
169 Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009;9:110. [PMID: 19358705 DOI: 10.1186/1471-2407-9-110] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
170 Amonkar SJ, Irving M, Wayman J, Sriram T, Griffin SM, Nicoll JJ, Raimes SA. The changing use of palliative chemotherapy for recurrent esophagogastric cancer: a single center retrospective 15-year review. J Gastrointest Cancer 2008;39:51-7. [PMID: 19238591 DOI: 10.1007/s12029-009-9051-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Inoue K, Nakane Y, Michiura T, Yamaki S, Yui R, Sakuramoto K, Iwai A, Tokuhara K, Araki Y, Kim S. Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer. Surg Endosc. 2009;23:2307-2313. [PMID: 19184202 DOI: 10.1007/s00464-008-0324-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
172 Ohashi M, Kanda T, Hirota M, Kobayashi T, Yajima K, Kosugi S, Hatakeyama K. Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer. Surg Today 2008;38:1102-7. [PMID: 19039635 DOI: 10.1007/s00595-007-3749-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
173 Catalano V, Graziano F, Santini D, D’Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer. 2008;99:1402-1407. [PMID: 18971936 DOI: 10.1038/sj.bjc.6604732] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
174 Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008;17:831-43. [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
175 McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008;98:888-93. [PMID: 18268490 DOI: 10.1038/sj.bjc.6604248] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
176 Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008;98:832-839. [PMID: 18231104 DOI: 10.1038/sj.bjc.6604211] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 5.2] [Reference Citation Analysis]
177 Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63. [PMID: 17680847 DOI: 10.1111/j.1572-0241.2007.01437.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 7.7] [Reference Citation Analysis]
178 Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, Takahashi Y, Ohnuma H, Kuroiwa G, Miyanishi K, Takimoto R, Matsunaga T, Kato J, Yamaguchi K, Hirata K, Niitsu Y. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 2007;97:851-6. [PMID: 17848958 DOI: 10.1038/sj.bjc.6603957] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
179 Wilson D. Docetaxel in gastric cancer: a viewpoint by David Wilson. Drugs 2007;67:1902-3. [PMID: 17722958 DOI: 10.2165/00003495-200767130-00009] [Reference Citation Analysis]
180 Hosokawa A, Sugiyama T, Ohtsu A, Doi T, Hattori S, Kojima T, Yano T, Minashi K, Muto M, Yoshida S. Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol 2007;42:533-8. [PMID: 17653648 DOI: 10.1007/s00535-007-2059-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
181 Amoroso V, Pittiani F, Grisanti S, Valcamonico F, Simoncini E, Ferrari VD, Marini G. Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria. BMC Cancer. 2007;7:94. [PMID: 17540044 DOI: 10.1186/1471-2407-7-94] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
182 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
183 Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006;94:637-41. [PMID: 16479253 DOI: 10.1038/sj.bjc.6602998] [Cited by in Crossref: 199] [Cited by in F6Publishing: 208] [Article Influence: 12.4] [Reference Citation Analysis]
184 Zhang J, Zhu ZG, Ji J, Yuan F, Yu YY, Liu BY, Lin YZ. Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. World J Gastroenterol 2005; 11(15): 2213-2217 [PMID: 15818728 DOI: 10.3748/wjg.v11.i15.2213] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]